Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Keio Spinoff Taps Nikon as CDMO, Targets 2027 Start for KP8011 Trial
K Pharma, a Keio University offshoot, said on February 24 that it has sealed a basic manufacturing agreement with Nikon Cell Innovation as CDMO for its company-sponsored PI/II trial of KP8011, an iPS cell-derived regenerative medicine product for spinal cord…
To read the full story
Related Article
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
- Nikon Bets 10 Billion Yen on Regenerative Medicine CDMO Push
September 22, 2025
BUSINESS
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
- Guardant360 Snags Japan OK as CDx for AZ’s Camizestrant
April 28, 2026
- Meiji Begins Japan PI/II Trial of Rezurock in Pediatric GVHD
April 28, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…